SALT LAKE CITY, Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...
The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY, ...
Meet DCN Dx Experts at Booth #120, October 16-19, 2024 in Los Angeles CARLSBAD, Calif., Oct. 1, 2024 /PRNewswire/ -- DCN Dx, a global leader in diagnostic development and clinical research services, ...
SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback